Status:
WITHDRAWN
Pancreatic Enzyme Suppletion in Pancreatic Cancer
Lead Sponsor:
Foundation for Liver Research
Conditions:
Adenocarcinoma of the Pancreas
Normal Pancreatic Exocrine Function
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly ...
Detailed Description
Weight loss in cancer is caused by primary tumour effects and secondary effects (e.g. side effects of treatment, mechanical and intestinal obstruction). In pancreatic cancer, additional weight loss an...
Eligibility Criteria
Inclusion
- Adenocarcinoma of the pancreas (histologically confirmed)
- Normal exocrine pancreatic function (Fecal Elastase test \> 0.2 mg/g)
- Capable and willing to follow instructions given by the physician.
Exclusion
- Other causes of fat malabsorption (celiac disease, IBD, and major gastrointestinal surgery).
- \< 18 years.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01401387
Start Date
October 1 2011
End Date
May 1 2013
Last Update
February 22 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3000 WB